<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804852</url>
  </required_header>
  <id_info>
    <org_study_id>WP-2020-04</org_study_id>
    <nct_id>NCT04804852</nct_id>
  </id_info>
  <brief_title>Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head &amp; Neck Cancer</brief_title>
  <acronym>SARVADS 1</acronym>
  <official_title>Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head &amp; Neck Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weprom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weprom</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarcopenia is defined by the reduction in skeletal muscle mass and physical performance. It&#xD;
      results in a decrease in muscle strength, overall physical activity, walking and the&#xD;
      development of balance disorders and falls. It is one of the natural consequences of aging&#xD;
      and contributes to frailty and the appearance of geriatric syndrome (s) (Chandapasirt et al,&#xD;
      2015; Cruz-Jentoft et al, 2010).&#xD;
&#xD;
      Its prevalence in patients with Head &amp; Neck cancer is 39% (Hua et al, 2020) and is associated&#xD;
      with an increase in postoperative complications (Achim et al, 2017; Bril et al, 2019), with&#xD;
      greater toxicity of chemotherapy. (Wendrich et al, 2017) and reduced overall survival (Hua et&#xD;
      al, 2020).&#xD;
&#xD;
      It is measured by CT scan (assessment of muscle volume with respect to L3 using IMAGE J&#xD;
      software) (Teigen et al, 2018) and by clinical tests (performance tests) (Swartz et al, 2016,&#xD;
      Cruz-Jentoft et al, 2010).&#xD;
&#xD;
      Several studies have shown a possible assessment of sarcopenia by measuring skeletal muscle&#xD;
      mass with regard to C3 (Ufuk et al, 2019; Swartz et al, 2016).&#xD;
&#xD;
      This trial aims to evaluate the prevalence of sarcopenia in head and neck cancer evaluated by&#xD;
      CT at C3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the prevalence of sarcopenia by cervical CT scan (C3)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with sarcopenia at diagnosis and during treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of hypoalbuminemia</measure>
    <time_frame>6 month</time_frame>
    <description>Number of patients presenting an hypoalbuminemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>De- and undernutrition</measure>
    <time_frame>6 month</time_frame>
    <description>Number of patients with a BMI &lt;18 and with a prescription for nutritional complements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to the treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients having the complete planned treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with a complete response on the end-of-treatment evaluation scanner according to the RECIST or PERCIST criteria in the numerator out of the total number of patients in the denominator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of hospitalizations treatment-related complications</measure>
    <time_frame>6 months</time_frame>
    <description>Number of hospitalizations per patient for treatment-related complications</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Cancer of Head and Neck</condition>
  <condition>CT Scan</condition>
  <arm_group>
    <arm_group_label>study population</arm_group_label>
    <description>Patient diagnosed with head &amp; neck carcinoma at diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sarcopenia assessment</intervention_name>
    <description>evaluation of sarcopenia by CT san at the C3 vertebrae</description>
    <arm_group_label>study population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient diagnosed with head &amp; neck carcinoma non operable and treated by radiotherapy&#xD;
        and/or chemotherapy and/or targeted therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient over 18 years old,&#xD;
&#xD;
          -  affiliated to the social security scheme,&#xD;
&#xD;
          -  suffering from locally advanced head &amp; neck cancer (stages I to IVB) at diagnosis,&#xD;
&#xD;
          -  not operable,&#xD;
&#xD;
          -  justifying treatment by radiotherapy, whether or not associated with chemotherapy or&#xD;
             targeted therapy (eg: monoclonal antibodies, immunotherapy) whatever the proposed&#xD;
             modalities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient treated by non-conservative surgery and cervical lymph node dissection making&#xD;
             it impossible to assess muscle mass with regard to C3,&#xD;
&#xD;
          -  metastatic disease,&#xD;
&#xD;
          -  minor patient,&#xD;
&#xD;
          -  adult patient under guardianship,&#xD;
&#xD;
          -  pregnancy or breastfeeding in progress.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LE DU Katell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Weprom</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magali BALAVOINE</last_name>
    <phone>241682940</phone>
    <phone_ext>0033</phone_ext>
    <email>m.balavoine@weprom.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonas DUBU</last_name>
    <email>jonas.dubu@i-l-c.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Victor Hugo / Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas DUBU</last_name>
      <phone>+33 769510938</phone>
      <email>jonas.dubu@i-l-c.fr</email>
    </contact>
    <investigator>
      <last_name>Katell LE DÃ›, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amandine RUFFIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

